ArticleScientific reports2025
Exploring the anticancer potential of green silver Nanoparticles-Paclitaxel nanocarrier on MCF-7 breast Cancer cells: an in vitro approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes.Pharmaceutical research · 2026Article
- Green synthesized silver and zinc oxide nanoparticles with antifungal, DNA protection, DNA cleavage, and cytotoxic activities.Scientific reports · 2026Article
- Molecular identification, characterization and antibacterial activity of fungal-mediated silver nanoparticles against Bacillus subtilis sh3 and Klebsiella pneumoniae sh4.Scientific reports · 2026Article
- Green Synthesized Silver Nanoparticles from Meyna Laxiflora: Binding with HSA and Anti-biofilm Potential.Cell biochemistry and biophysics · 2026Article
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Synergistic induction of apoptosis in cancer cells by combined silver nanoparticles and paclitaxel.Iranian journal of basic medical sciences · 2026Article
- Microbial-Based Green Synthesis of Silver Nanoparticles: A Comparative Review of Bacteria- and Fungi-Mediated Approaches.International journal of molecular sciences · 2025Review
- Curcumin-Loaded Nanomaterials as Carriers for Photodynamic Therapy Against Cancers.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel (PTX) is a potent chemotherapeutic agent limited by poor solubility and adverse effects. To address these challenges, we developed a novel nanocomposite combining PTX purified from the endophytic fungus A. fumigatiaffinis PP235788.1 with biosynthesized silver nanoparticles (AgNPs) from the same fungal strain. The PTX-AgNP conjugate (28.48 ± 0.13 nm) was characterized by UV-Vis, XRD, and TEM, revealing monodisperse AgNPs (14.50 ± 0.58 nm) as the core component. In vitro studies demonstrated significant cytotoxicity against MCF-7 breast cancer cells (IC₅₀= 1.7 µg/mL, p < 0.001), with 5-10-fold greater efficacy than AgNPs alone. Annexin V/PI staining and DNA fragmentation assays confirmed apoptosis induction, highlighting the conjugate's enhanced anticancer activity. This eco-friendly nano platform synergizes PTX's therapeutic effects with AgNP-mediated targeting, offering a promising strategy to reduce side effects while improving tumor-specific cytotoxicity for advanced cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.